XML 31 R19.htm IDEA: XBRL DOCUMENT v3.26.3
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 11. SUBSEQUENT EVENTS

 

On October 27, 2026 (the “First Amendment Effective Date”), the Company entered into the First Amendment to Loan Agreement (the “Amendment”) with The Patel Family, LLP (the “Lender”), amending the Loan Agreement, dated as of June 6, 2024, between the Company and the Lender (the “Original Agreement” and, as amended by the Amendment, the “Amended Loan Agreement”).

 

The Amendment, among other things: (i) extends the period during which the Company can request borrowings under the Facility from May 31, 2027 to May 31, 2029; (ii) replaces the $1.0 million limit on each monthly draw and permits the Company, subject to the terms and conditions of the Amended Loan Agreement, to borrow at least $1.0 million per month, or such lesser or greater amount as the Company specifies, with aggregate post-amendment borrowings limited to $28.6 million; and (iii) sets a fixed price of $7.40 per share (the “Share Purchase Price”) for shares issued in payment of principal (“Principal Shares”) and interest (“Interest Shares”), including accrued but unpaid interest as of the First Amendment Effective Date, replacing the prior $75.00 per-share interest price and $75.00 per-share floor applicable to principal payments; (iv) adds stock-lending, first-year resale-volume and transfer restrictions applicable to shares issued under the Amended Loan Agreement; (v) fixes the Lender’s beneficial ownership limitation (the “Beneficial Ownership Limitation”) at 9.99% by removing the Lender’s ability to increase or decrease that percentage by notice; (vi) updates the measurement date for the Amended Loan Agreement’s 19.99% issuance cap (the “Issuance Cap”) from the date of the Original Agreement to the First Amendment Effective Date; and (vii) changes resale registration requirements for Principal Shares and related pre-funded warrants from pre-issuance effectiveness to filing within 15 calendar days after issuance.

 

As of the First Amendment Effective Date, the outstanding principal balance of the loans borrowed under the Original Agreement was $7.4 million. The Amended Loan Agreement continues to permit the Company, at its sole election, to repay principal in cash or shares of Common Stock. Following the Amendment, on October 29, 2026, the Company elected to repay the entire outstanding principal balance, together with $177,880 of accrued and unpaid interest, in shares of common stock at the Share Purchase Price. On November 2, 2026, the Company issued to the Lender 1,000,000 Principal Shares and 23,733 Interest Shares in payment thereof thereby eliminating all outstanding liabilities under the Amended Loan Agreement.

 

Subsequent to this repayment, assuming the Company borrows the full $28.6 million remaining available under the Facility, makes no prepayments, the interest rate on each borrowing is the maximum rate of 7.00% per annum, each borrowing remains outstanding for its full 48-month term, the Company pays all principal in shares of common stock in a single payment, and the PIPE is consummated at the minimum applicable price, up to approximately 4.99 million shares of additional common stock may be issuable under the Amended Loan Agreement, subject to the Beneficial Ownership Limitation and the Issuance Cap.

 

On November 2, 2026, the Company made a grand of 50,000,000 shares of Restricted Stock to Dr. Saadi. The shares of Restricted Stock will vest if the Company has $1 billion in aggregate revenue by December 30, 2031. Pursuant to the terms of this award, Dr. Saadi is entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to automatic forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock in the event he departs the Company for any reason.

 

In October 2026, the Company declared and settled 13.0113 Series C PIK shares.